Amy A. Kirkwood

90 Tottenham Court Road, W1T 4TJ
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 89 publications

Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 27, 2026

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 11, 2026

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

Journal: British journal of haematology

Published: February 25, 2026

Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.

Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.

Journal: Blood advances

Published: January 21, 2026

Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.

Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.

Journal: Blood advances

Published: January 21, 2026

New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging System.

New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging System.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 07, 2025

CAR-T therapy for relapsed/refractory large B-cell lymphoma in people living with HIV: efficacy, toxicity and treatment considerations.

CAR-T therapy for relapsed/refractory large B-cell lymphoma in people living with HIV: efficacy, toxicity and treatment considerations.

Journal: Haematologica

Published: November 04, 2025

Front-line systemic treatment outcomes in POEMS syndrome.

Front-line systemic treatment outcomes in POEMS syndrome.

Journal: British journal of haematology

Published: September 27, 2025

Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK.

Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK.

Journal: HemaSphere

Published: September 05, 2025

Reply to: "UKALL 2011: Flawed Noninferiority and Overlooked Interactions Undermine Conclusions" and "Understanding the Potential Importance of Pharmacokinetic Variability in the Setting of ALL".

Reply to: "UKALL 2011: Flawed Noninferiority and Overlooked Interactions Undermine Conclusions" and "Understanding the Potential Importance of Pharmacokinetic Variability in the Setting of ALL".

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 14, 2025

High-Dose Methotrexate in Children and Young Adults With ALL and Lymphoblastic Lymphoma: Results of the Randomized Phase III Study UKALL 2011.

High-Dose Methotrexate in Children and Young Adults With ALL and Lymphoblastic Lymphoma: Results of the Randomized Phase III Study UKALL 2011.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 07, 2025

CD19 chimeric antigen receptor T-cell efficacy and toxicity in adults with Richter's transformation and response to bridging therapy.

CD19 chimeric antigen receptor T-cell efficacy and toxicity in adults with Richter's transformation and response to bridging therapy.

Journal: British journal of haematology

Published: March 01, 2025

Showing 1-12 of 89

Last Updated: 09/26/2026